Leezole-3 Kit Tablet is a combination pharmaceutical formulation containing Fluconazole 150 mg, Azithromycin 1000 mg, and Secnidazole 1000 mg, designed for the treatment of mixed infections involving fungal, bacterial, and protozoal pathogens. Fluconazole, a triazole antifungal agent, inhibits fungal cytochrome P450 enzymes, disrupting ergosterol synthesis and thereby compromising fungal cell membrane integrity. Azithromycin, a macrolide antibiotic, exerts bacteriostatic effects by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis, and is effective against a broad spectrum of Gram-positive and Gram-negative bacteria. Secnidazole, a nitroimidazole derivative, demonstrates potent activity against anaerobic protozoa and bacteria by inducing DNA strand breaks and inhibiting nucleic acid synthesis. This combination is particularly indicated in complex infections such as mixed vaginitis, pelvic inflammatory disease, and other polymicrobial infections where concurrent fungal, bacterial, and protozoal pathogens are implicated. Leezole-3 Kit Tablet should be administered under medical supervision, with dosage tailored according to infection severity and patient-specific factors. Caution is advised in patients with hepatic or renal impairment, and potential drug interactions must be considered. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and, rarely, hepatotoxicity. Patient adherence and monitoring are essential to ensure therapeutic efficacy and minimize resistance development.